Switch Therapeutics
Joonhee Han is a seasoned scientist with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as a Principal Scientist at Switch Therapeutics since 2023, Joonhee has previously held key positions, including Director - Project Scientist IV at Myriad Genetics in 2022 and Senior Scientist - Manager at Adaptive Biotechnologies Corp. from 2020 to 2022. Joonhee's career spans various roles, such as Senior Scientist at PPD, Essenlix Corporation, MeiraGTx, and ANDalyze, along with Postdoctoral Researcher positions at The Ohio State University, UC San Diego, and Yale University. Joonhee completed a Ph.D. in Microbiology & Molecular Genetics from the University of Vermont in 2005.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.